Myovant's Relugolix May Be Competitive With AbbVie Drug In Uterine Fibroids
Executive Summary
Relugolix meets primary and six key secondary endpoints in first Phase III UF study. Magnitude of benefit for primary endpoint does not equal AbbVie’s elagolix, but Myovant thinks it will offer safety, tolerability and convenience advantages.
You may also be interested in...
Myovant Ready To File Relugolix For Prostate Cancer
Secondary endpoint assessing cardiovascular risk may offer important differentiation from AbbVie’s Lupron. Myovant accelerated the prostate cancer filing soon after slowing the planned relugolix submission for uterine fibroids.
Myovant Plans Q4 Uterine Fibroid Drug Filing In A Showdown With AbbVie
A second Phase III trial testing relugolix met its primary endpoint, putting Myovant in a tight race with AbbVie to bring the first drug to market for women with uterine fibroids.
Finance Watch: Third Rock Raises $770m To Launch Up To 12 New Companies
The VC firm known for its new company formation efforts will launch 10-12 biopharma, device and diagnostic ventures with its fifth fund. Also, EpimAb raises a $74m series B round, three more drug developers join the IPO queue and Amicus leads recent follow-on offerings.